HRS-9821 vs KIT2014

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline

HRS-9821

Developed by GlaxoSmithKline and partners

Phase 2 in Chronic Obstructive Pulmonary Diseasesmall molecule
Weak signal

NCT05622864 · Phase 1 · completed

The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Assess the incidence and severity of adverse events after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

KIT2014

Developed by Kither Biotech

Phase 1/2 in Chronic Obstructive Pulmonary Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07668518 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-9821KIT2014
Moderate or severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
SGRQ total, change—Not reported—Not reported
TDI focal score—Not reported—Not reported

Moderate or severe exacerbations, annualised rate

HRS-9821
—Not reported
KIT2014
—Not reported

Trough FEV1, change

HRS-9821
—Not reported
KIT2014
—Not reported

SGRQ total, change

HRS-9821
—Not reported
KIT2014
—Not reported

TDI focal score

HRS-9821
—Not reported
KIT2014
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-9821: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

KIT2014: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-9821's landscape · KIT2014's landscape